Figure 2 – Comparison study of Canapure (( - ) -CBD ) and hemp derived ( - ) -CBD
effects on CB1 are antagonistic for both ( - ) -CBD-qualities . On CB2 , as well as on GPR55 , solely agonistic effects were observed . Thus , it can be concluded that there is no significant difference in the biological value of pure natural ( - ) -CBD and natureidentical Canapure . Among the further question which comes up from the regulatory point of view is whether the enantiomeric purity of Canapure is equivalent to that of naturally derived CBD and whether there are (+) -CBD impurities . The raw material D-limonene is enantiomerically pure and racemisation during the course of the synthesis is not observed . The stereochemistry of the starting material induces the stereochemical outcome of the desired ( - ) -CBD and does not allow the formation of (+) - CBD . In addition , the optical rotation results are in perfect accordance to the known literature for ( - ) -CBD . However , all these arguments are not precise enough from a regulatory perspective . To prove the absence of (+) -CBD , Symrise used a special enantiomeric analysis ( via GC and UHPLC ) for product analysis and crystallographic characterisation by X-ray crystallography . The synthesis of (+) -CBD and its full chemical and physical characterisation were decisive .
(+) -CBD was not commercially available on the market . Consequently , Symrise has invented a new , patentpending pathway . Subsequently ,
Figure 3 : Separation of ( - ) - & (+) - CBD by chiral GC ( UHPLC )
chiral GC and UHPLC methods were developed to separate ( - ) - and (+) - CBD . This enabled Symrise to prove the absence of (+) -CBD , which is another step forward to the safety of Canapure . The clear separation of both products made by chiral UHPLC is shown in Figure 3 . The violet coloured peak is the (+) -CBD and on the right in green is the ( - ) -CBD . The last part of the proof is the X-ray structure analysis done at the Max Planck Institute in Germany . The absolute configuration of tested Canapure corresponds to the crystallographic structure of (( - ) -trans-CBD ).
Conclusion
Canapure ( - ) -CBD of nature-identical origin has the same biological value as the ( - ) -CBD extracted from the cannabis plant . The absolute configuration of Canapure is the same as that of
(( - ) -trans-CBD ). This supports the use of Canapure for the same applications , irrespective of its origin , paving the way for trustworthy GMP CBD . In addition , other synthetic and / or nature-identical cannabinoids , such as (+) -CBD , showed a significantly higher affinity in vitro to the cannabinoid receptors compared to ( - ) -CBD . These active ingredients , as well as CBDV and CBG , open up new opportunities for the pharmaceutical industry . •
* Canapure is a registered trademark by Symrise being used for nature-identical ( - ) -CBD
Silke Hilmer
GLOBAL MARKETING DIRECTOR
21